Masking the transmembrane region of the amyloid β precursor protein as a safe means to lower amyloid β production

Abstract Introduction Reducing brain levels of both soluble and insoluble forms of amyloid beta (Aβ) remains the primary goal of most therapies that target Alzheimer's disease (AD). However, no treatment has so far resulted in patient benefit, and clinical trials of the most promising drug cand...

Full description

Bibliographic Details
Main Authors: Ayesha Khan, Richard Killick, Daniel Wirth, Dominique Hoogland, Kalina Hristova, Jakob P. Ulmschneider, Christopher R. King, Martin B. Ulmschneider
Format: Article
Language:English
Published: Wiley 2023-10-01
Series:Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Subjects:
Online Access:https://doi.org/10.1002/trc2.12428